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OBJECTIVES The purpose of this study was to assess the efficacy and safety of ezetimibe administered with
simvastatin in patients with primary hypercholesterolemia.
BACKGROUND Despite the availability of statins, many patients do not achieve lipid targets. Combination
therapy with lipid-lowering agents that act via a complementary pathway may allow
additional patients to achieve recommended cholesterol goals.
METHODS After dietary stabilization, a 2- to 12-week washout period, and a 4-week, single-blind,
placebo lead-in period, patients with baseline low-density lipoprotein cholesterol (LDL-C)
145 mg/dl to 250 mg/dl and triglycerides (TG) 350 mg/dl were randomized to one of
the following 10 groups administered daily for 12 consecutive weeks: ezetimibe 10 mg;
simvastatin 10, 20, 40, or 80 mg; ezetimibe 10 mg plus simvastatin 10, 20, 40, or 80 mg; or
placebo. The primary efficacy variable was percentage reduction from baseline to end point in
direct LDL-C for the pooled ezetimibe plus simvastatin groups versus pooled simvastatin
groups.
RESULTS Ezetimibe plus simvastatin significantly improved LDL-C (p  0.01), high-density lipopro-
tein cholesterol (HDL-C) (p  0.03), and TG (p  0.01) compared with simvastatin alone.
Ezetimibe plus simvastatin (pooled doses) provided an incremental 13.8% LDL-C reduction,
2.4% HDL-C increase, and 7.5% TG reduction compared with pooled simvastatin alone.
Coadministration of ezetimibe and simvastatin provided LDL-C reductions of 44% to 57%,
TG reductions of 20% to 28%, and HDL-C increases of 8% to 11%, depending on the
simvastatin dose. Ezetimibe 10 mg plus simvastatin 10 mg and simvastatin 80 mg alone each
provided a 44% LDL-C reduction. The coadministration of ezetimibe with simvastatin was
well tolerated, with a safety profile similar to those of simvastatin and of placebo.
CONCLUSIONS When coadministered with simvastatin, ezetimibe provided significant incremental reduc-
tions in LDL-C and TG, as well as increases in HDL-C. Coadministration of ezetimibe with
simvastatin was well tolerated and comparable to statin alone. (J Am Coll Cardiol 2002;40:
2125–34i) © 2002 by the American College of Cardiology Foundation
Despite the impressive low-density lipoprotein cholesterol
(LDL-C)–lowering efficacy of statins, the most commonly
prescribed cholesterol-lowering agents, a substantial per-
centage of patients require additional LDL-C reduction
beyond that achieved by current statin regimens to attain
the target levels recommended by the National Cholesterol
Education Program Adult Treatment Panel III (NCEP
ATP III) (1). Combination drug therapy with currently
See page 2135
available lipid-modifying agents (e.g., statins, fibric acid
derivatives, bile acid sequestrants, and niacin) may offer a
significant advantage over monotherapy, potentially allow-
ing more patients to achieve target cholesterol goals. How-
ever, combination therapy is often limited by an increased
risk of side effects, intolerance, noncompliance, or drug
interactions (2–6).
Ezetimibe is a member of a new class of lipid-altering
agents that inhibits the absorption of dietary and biliary
cholesterol without affecting the absorption of triglycerides
(TG) or fat-soluble vitamins (7–9). Because ezetimibe
inhibits the intestinal absorption of cholesterol (the molec-
ular mechanism of action of ezetimibe is currently being
investigated), it was hypothesized that the lipid-altering
effect of ezetimibe might be complementary to that of
agents that inhibit synthesis of cholesterol, such as statins.
Results from two pilot clinical pharmacology studies assess-
ing the pharmacokinetic and pharmacodynamic interaction
between ezetimibe and simvastatin in subjects with primary
hypercholesterolemia suggested that coadministration of
these two agents had an additive effect on LDL-C reduc-
tion, did not affect the pharmacokinetics of simvastatin, and
was safe and well tolerated (10,11).
The study reported here was designed to assess whether
ezetimibe 10 mg coadministered with simvastatin in pa-
tients with primary hypercholesterolemia, versus treatment
with simvastatin alone, produced incremental reductions in
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LDL-C while maintaining a similar safety profile. Second-
ary objectives were to evaluate the change from baseline for
additional lipid variables. Additionally, the proportions of
patients reaching NCEP ATP II and ATP III target levels
for direct LDL-C at study end point were examined in an
exploratory manner.
METHODS
Patients. This was a multicenter trial conducted at 61
study centers in the U.S. The protocol was reviewed and
approved by each institution’s Institutional Review Board or
Independent Ethics Committee. All patients provided writ-
ten informed consent. Men and women ages 18 years and
older with primary hypercholesterolemia (plasma LDL-C
concentration 145 mg/dl to 250 mg/dl, as calculated by
the Friedewald equation [12], and TG 350 mg/dl) were
considered eligible for study participation.
Prohibited concomitant illnesses and procedures included
congestive heart failure (defined as New York Heart Asso-
ciation class III or IV heart failure) (13); uncontrolled
cardiac arrhythmias; history of unstable or severe peripheral
artery disease within three months of study entry; unstable
angina pectoris; myocardial infarction, coronary bypass sur-
gery, or angioplasty within six months of study entry;
uncontrolled or newly diagnosed (within one month of
study entry) diabetes mellitus; active or chronic hepatic or
hepatobiliary disease; known impairment of renal function;
known coagulopathy; and unstable endocrine disease.
Study design. This multicenter, randomized, double-
blind, placebo-controlled, 2  5 factorial study consisted of
three phases (Fig. 1). During the 2- to 12-week washout
period, all lipid-altering drugs were discontinued, and pa-
tients were instructed regarding the NCEP Step I (or
stricter) diet (14). The subsequent four weeks constituted
the single-blind, placebo lead-in period. At Visit 2 (Q1) and
Visit 3 (Q2), blood samples were collected to assay for
qualifying lipid values; the mean value of plasma LDL-C
Abbreviations and Acronyms
ALT  alanine aminotransferase
AST  aspartate aminotransferase
CPK  creatine phosphokinase
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
NCEP ATP  National Cholesterol Education Program
Adult Treatment Panel
TC  total cholesterol
TG  triglycerides
ULN  upper limit of normal
Figure 1. Study design. *Q1  first qualifying LDL-C value using the Friedewald calculation; Q2  second qualifying LDL-C value using the Friedewald
calculation; blood samples for Q1 and Q2 were collected at least one week apart. †Randomization to double-blind treatment occurred at Visit 4. NCEP 
National Cholesterol Education Program.
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for Q1 and Q2 had to be145 mg/dl and250 mg/dl, with
no single value 145 mg/dl or 250 mg/dl. At Visit 4,
qualifying patients were randomized to receive one of the
following 10 treatments administered orally once daily for
12 consecutive weeks: ezetimibe 10 mg (Merck/Schering-
Plough Pharmaceuticals, Inc., Kenilworth, New Jersey);
simvastatin 10, 20, 40, or 80 mg (Merck & Co., Inc.,
Rahway, New Jersey); ezetimibe 10 mg plus simvastatin 10,
20, 40, or 80 mg; or placebo. Balanced randomization across
treatment groups was accomplished using a single
computer-generated randomization schedule with treat-
ment codes in blocks of 10. Patients maintained the NCEP
(or stricter) diet throughout the study and completed
three-day diet diaries between prespecified visits. Diary
entries were analyzed by Professional Nutrition Systems,
Inc. (Overland Park, Kansas), the central diet analysis
center.
Blood samples for lipid measurements were collected at
baseline and at Weeks 2, 4, 8, and 12; samples for
high-density lipoprotein cholesterol (HDL-C) subfractions,
apolipoproteins, and lipoprotein (a) were measured at base-
line and Week 12. Evaluation of safety was accomplished
through reports of patients, observations of investigators,
and results of specific tests and measurements (laboratory
tests, electrocardiograms, physical examinations, and vital
signs).
Laboratory methods. Medical Research Laboratories
(Highland Heights, Kentucky) performed all clinical labo-
ratory analyses. Lipid results were blinded to the investiga-
tors and study sponsor beginning with the first qualifying
lipid value. The LDL-C concentration was measured di-
rectly by ultracentrifugation (beta-quantification) and also
calculated via the Friedewald equation (12): LDL-C total
cholesterol (TG 5)HDL-C. Total cholesterol (TC)
and TG concentrations were quantified enzymatically with
the Hitachi 747 analyzer (Roche Diagnostics Corporation,
Indianapolis, Indiana). The HDL-C was determined enzy-
matically after LDL-C and very low-density lipoprotein
cholesterol had been selectively removed by heparin and
manganese chloride precipitation. The HDL3-C subfrac-
tion was quantified enzymatically after separation by ultra-
centrifugation, and the HDL2-C subfraction was calculated
with the following equation: HDL2-C  HDL-C 
HDL3-C. Apolipoprotein A-I and apolipoprotein B were
determined by fixed-rate nephelometry. Lipoprotein (a) was
quantified by competitive enzyme-linked immunosorbent
assay. Non-HDL-C was calculated using the following
equation: non-HDL-C  TC  HDL-C.
Statistical analysis. The primary efficacy variable was the
percentage reduction in direct LDL-C from baseline to
study end point (last postbaseline measurement) for the
intent-to-treat population. The primary hypothesis was that
the coadministration of ezetimibe 10 mg/day with simva-
statin (pooled across all doses) would result in a significantly
greater reduction in direct LDL-C when compared with
simvastatin alone (pooled across all doses). The primary
efficacy analysis was performed using a two-way analysis of
variance model that extracted effects due to dose (simvasta-
tin: 0, 10, 20, 40, and 80 mg), treatment (ezetimibe 10 mg
and placebo), and treatment-by-dose interaction. The com-
parisons (pooled ezetimibe 10 mg plus simvastatin [10, 20,
40, 80 mg] group vs. pooled simvastatin [10, 20, 40, 80 mg]
group and pooled ezetimibe 10 mg plus simvastatin [10, 20,
40, 80 mg] group vs. ezetimibe 10 mg group) were per-
formed using contrast statements under the model to
evaluate the primary hypothesis. Consistency of the treat-
ment effect across subgroups (gender, age [65 years, 65
years], race [white, non-white]), and treatment-by-factor
(defining such subgroups) interactions were evaluated for
the primary variable in the intent-to-treat population using
analysis of variance models, including factors for treatment,
dose, treatment-by-dose, subgroup, and treatment-by-
subgroup interaction. With the planned sample size of
approximately 650 patients (65 patients per treatment
group), a difference between percentage reduction of directly
measured LDL-C of any two individual treatment groups of
5 percentage points could be detected with 80% power
and a significance level of p  0.05 (two-tailed), assuming
a standard deviation of 10.
Change from baseline to end point was also evaluated for
the secondary lipid variables: calculated LDL-C, TC, TG,
HDL-C, apolipoprotein B, non-HDL-C, HDL2-C,
HDL3-C, apolipoprotein A-I, lipoprotein (a), and direct
LDL-C:HDL-C and TC:HDL-C ratios. For evaluation of
TG, a nonparametric evaluation using a one-way analysis of
variance on the ranks extracting effect for treatment (10
groups) was performed to complement the parametric
analysis. All statistical analyses were conducted using SAS
software (version 8).
RESULTS
Patient characteristics. Of 2,645 individuals screened, 668
(25%) met the eligibility criteria and were randomized. Of
the 668 patients, 591 (88%) completed the double-blind
treatment phase, whereas 77 (12%) discontinued study
treatment early because of an adverse event (42 patients),
patient request (18 patients), noncompliance with protocol
(13 patients), or loss to follow-up (4 patients). Of the 42
patients who discontinued study treatment early owing to an
adverse event, 14 received simvastatin monotherapy (4
simvastatin 10 mg, 6 simvastatin 20 mg, 2 simvastatin 40
mg, 2 simvastatin 80 mg), 20 received coadministration
therapy (2 ezetimibe plus simvastatin 10 mg, 7 ezetimibe
plus simvastatin 20 mg, 3 ezetimibe plus simvastatin 40 mg,
8 ezetimibe plus simvastatin 80 mg), five received ezetimibe
10 mg monotherapy, and three received placebo. There was
no pattern or trend across treatment groups in the distribu-
tion of patients who discontinued or in the reasons for
discontinuation.
Demographics and baseline characteristics of the treat-
ment groups were similar (Table 1). The intent-to-treat
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population consisted of 377 women and 291 men, 25 to 87
years of age, with hypercholesterolemia characterized by
plasma concentrations of direct LDL-C from 137 to 247
mg/dl. Mean baseline plasma concentrations of direct
LDL-C ranged from 174 to 182 mg/dl across treatment
groups. Compliance data (mean percentages of total doses
taken) ranged from approximately 90% to 97%.
Efficacy. Coadministration of ezetimibe plus simvastatin
(pooled doses) was significantly more effective than simva-
statin alone (pooled doses) in reducing plasma levels of
direct LDL-C from baseline to end point, as evidenced by
a mean percentage change of 49.9% for coadministration
versus 36.1% for simvastatin alone (p  0.01) (Table 2).
Similarly, coadministration of ezetimibe plus simvastatin
(pooled) was more efficacious than ezetimibe alone (mean
percentage change in direct LDL-C from baseline to end
point of 49.9% vs. 18.1%) (p  0.01). Across the
individual treatment groups, mean percentage changes in
direct LDL-C from baseline to end point ranged from
approximately 44% to 57% for coadministration versus
27% to 44% for simvastatin monotherapy (Fig. 2A).
The incremental mean percentage change resulting from the
coadministration of ezetimibe with each dose of simvastatin
was statistically significant (p  0.01) when compared with
each corresponding dose of simvastatin monotherapy and
between ezetimibe plus simvastatin 10 mg and both simva-
statin 20 mg and simvastatin 40 mg alone, and between
ezetimibe plus simvastatin 20 mg and simvastatin 40 mg
alone. The mean percentage change in LDL-C achieved
with ezetimibe plus simvastatin 10 mg was numerically
similar to that with simvastatin 80 mg alone (approximately
44% in both cases). The incremental LDL-C-lowering
effects resulting from the coadministration of ezetimibe
with each dose of simvastatin were observed as early as
Week 2 and maintained for the duration of the study
(Fig. 3). The incremental reduction of LDL-C concentra-
tions with coadministration of ezetimibe and simvastatin
(all doses) was generally consistent across all subgroups
tested, including risk-factor status, gender, age, race, or
baseline lipid profile.
Results for calculated LDL-C were entirely consistent
with those obtained for direct LDL-C. Individually, all
coadministration treatment groups exhibited consistently
greater mean percent changes in calculated LDL-C from
baseline to end point (approximately 46%, 46%, 56%,
and 58%, respectively) compared with simvastatin alone
treatment groups (approximately27%,37%,38%, and
45%). The difference between each dose of simvastatin
plus ezetimibe 10 mg versus the same and the next higher
dose of simvastatin alone was statistically significant (p 
0.01). As with direct LDL-C, coadministration of
ezetimibe with simvastatin 10 mg resulted in a similar mean
percent change as simvastatin 80 mg monotherapy (46%
and 45%, respectively).
Ezetimibe plus simvastatin (pooled) also significantly
improved the following secondary efficacy variables com-
Table 1. Baseline Patient Characteristics
Characteristic
Placebo
(n  70)
Ezetimibe 10 mg
(n  61)
All Simvastatin*
(n  263)
Ezetimibe 10 mg 
All Simvastatin*
(n  274)
Age (yrs): mean (range) 58.8 (25–84) 60.3 (35–84) 56.4 (25–87) 57.6 (27–83)
No. patients  65 yrs 23 (33%) 21 (34%) 74 (28%) 84 (31%)
Females/Males 39 (56%)/31 (44%) 37 (61%)/24 (39%) 153 (58%)/110 (42%) 148 (54%)/126 (46%)
Race
White 67 (96%) 58 (95%) 237 (90%) 248 (91%)
Black 1 (1%) 1 (2%) 12 (5%) 11 (4%)
Hispanic 1 (1%) 2 (3%) 13 (5%) 9 (3%)
Asian 0 0 1 (1%) 6 (2%)
American Indian 1 (1%) 0 0 0
Baseline lipid values (mg/dl); mean (SD)
Direct LDL-C 177.4 (21.7) 181.3 (23.0) 178.5 (20.0) 176.3 (19.9)
Calculated LDL-C 179.1 (21.2) 183.3 (22.4) 180.1 (19.9) 177.6 (20.1)
HDL-C 52.3 (12.1) 51.0 (11.5) 51.0 (10.9) 50.4 (12.2)
TG 170.9 (68.5) 190.3 (68.2) 168.7 (59.8) 178.8 (65.1)
Family history of CHD 34 (49%) 29 (48%) 105 (40%) 117 (43%)
Current smoker 8 (11%) 9 (15%) 41 (16%) 37 (14%)
Currently physically active 48 (69%) 38 (62%) 152 (58%) 157 (57%)
History of hypertension/diabetes mellitus 21 (30%)/6 (9%) 18 (30%)/5 (8%) 76 (29%)/7 (3%) 82 (30%)/9 (3%)
Patient history of CHD 5 (7%) 3 (5%) 16 (6%) 23 (8%)
Washout information
Statin 19 (27%) 17 (28%) 74 (28%) 70 (26%)
Fibrate 0 0 2 (1%) 2 (1%)
Bile acid sequestrant 0 0 0 1 (1%)
Nicotinic acid 0 3 (5%) 5 (2%) 7 (3%)
Other 6 (9%) 7 (11%) 22 (8%) 13 (5%)
*All simvastatin  pool of all doses of simvastatin.
CHD coronary heart disease; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; SD standard deviation; TG triglycerides.
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pared with simvastatin alone (pooled) (Table 2): TG and
TC, apolipoprotein B, non-HDL-C, direct LDL-C:
HDL-C, and TC:HDL-C (p 0.01); HDL-C (p 0.03);
and HDL3-C (p  0.02). Figure 2 summarizes the changes
in LDL-C, HDL-C, and TG concentrations across the
individual treatment groups. Coadministration of ezetimibe
with simvastatin compared with simvastatin alone signifi-
cantly reduced direct LDL-C (Fig. 2A) at all simvastatin
doses (p 0.01), increased HDL-C at a simvastatin dose of
40 mg (Fig. 2B) (p  0.02), and reduced TG (Fig. 2C) at
simvastatin doses of 10 mg (p  0.01) and 80 mg (p 
0.02).
Overall, 59% (157/268) of patients who received coad-
ministration therapy compared with 15% (40/261) of pa-
tients who received simvastatin monotherapy achieved
50% reduction in plasma concentrations of direct LDL-C
at end point. Based on the NCEP ATP III guidelines, 77%
(207/268) of patients receiving coadministration therapy
compared with 64% (167/261) of patients receiving simva-
statin monotherapy had LDL-C concentrations above tar-
get levels at the start of treatment and below target at end
point (Table 3). The differences between the two pooled
treatment groups in the proportion of patients achieving
either NCEP ATP II or ATP III target LDL-C concen-
trations were statistically significant (p  0.01) (Table 3).
Safety. Treatment-emergent adverse events were reported
for 72% of subjects on simvastatin monotherapy and 69% of
subjects on coadministration therapy. The most common
adverse events included upper respiratory tract infection
(14% on simvastatin monotherapy vs. 15% on coadminis-
tration), headache (9% vs. 7%), and nausea (6% vs. 4%).
Treatment-related adverse events were reported for 19%
(50/263) of patients receiving simvastatin monotherapy and
20% (54/274) of patients receiving coadministration therapy
(Table 4). Profiles for nonlaboratory-related adverse events
were similar for the two pooled treatment groups. The types
of adverse events resulting in treatment discontinuation
(42/668, 5% of patients) or interruption (42/668, 5% of
patients) were generally no more common or severe in any
treatment group. Similar proportions of patients receiving
coadministration therapy compared with simvastatin mono-
therapy reported significant adverse events resulting in
discontinuation (7% [20/274] vs. 5% [14/263]) or interrup-
tion of study treatment (5% [15/274] vs. 7% [18/263]). One
case of mild hepatomegaly and one case of severe choleli-
thiasis/cholecystectomy were reported. Both of these events
occurred in patients receiving simvastatin monotherapy and
were considered unlikely related to study medication.
One patient died postrandomization approximately one
month after commencing study medication (ezetimibe plus
simvastatin 20 mg) as a result of hypotension and respiratory
failure secondary to a left middle cerebral artery infarction.
The investigator considered the death to be unlikely related
to study medication.
Patients were considered to have two consecutive post-
baseline elevations of alanine aminotransferase (ALT) orTa
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Figure 2. Percentage change in direct low-density lipoprotein cholesterol (A), high-density lipoprotein cholesterol (B), and triglyceride (C) concentrations
from baseline to end point. EZE  ezetimibe; Simva  simvastatin. Nonfilled columns  Simva; filled columns  Simva  EZE. In (A), the asterisk
denotes p  0.01, combination versus statin alone.
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aspartate aminotransferase (AST) if 1) there were two or
more consecutive values3 upper limit of normal (ULN);
2) the last value was 3 ULN; or 3) a measurement of
3 ULN during treatment or 2 days after the end of
treatment was followed by a measurement 3 ULN that
was taken 2 days after the last dose of study medication.
Eight patients, six receiving coadministration therapy
(1 ezetimibe plus simvastatin 20 mg, 4 ezetimibe plus
simvastatin 40 mg, 1 ezetimibe plus simvastatin 80 mg) and
two receiving simvastatin monotherapy (1 simvastatin 20
mg, 1 simvastatin 80 mg), had consecutive elevations 3
ULN for ALT and/or AST. Six patients of the eight cases,
including five receiving coadministration therapy, had ele-
vated ALT/AST levels at baseline (patients with elevations
up to 2 ULN at baseline were allowed into the study), and
four completed the study. All elevations in hepatic enzyme
Figure 3. Mean percent change from baseline in plasma concentration of direct low-density lipoprotein cholesterol (LDL-C) over time and at end point.
EZE  ezetimibe; Simva  simvastatin.
Table 3. Achievement of NCEP ATP II/III Target LDL-C at End Point
Placebo
(n  69)
Ezetimibe 10 mg
(n  59)
All Simvastatin*
(n  261)
Ezetimibe 10 mg 
All Simvastatin*
(n  268)
NCEP ATP II
Below goal at baseline 7 (10%) 7 (12%) 32 (12%) 39 (15%)
Below goal at end point 14 (20%) 28 (47%) 223 (85%) 252 (94%)
Below goal at end point only 7 (10%) 23 (39%) 191 (73%) 214 (80%)
Below goal at baseline only 0 2 (3%) 0 1 (1%)
NCEP ATP III
Below goal at baseline 9 (13%) 10 (17%) 32 (12%) 39 (15%)
Below goal at end point 15 (22%) 23 (39%) 198 (76%) 245 (91%)
Below goal at end point only 7 (10%) 15 (25%) 167 (64%) 207 (77%)
Below goal at baseline only 1 (1%) 2 (3%) 1 (1%) 1 (1%)
*All simvastatin  pool of all doses of simvastatin.
LDL-C  low-density lipoprotein cholesterol; NCEP ATP  National Cholesterol Education Program Adult Treatment
Panel.
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activity were asymptomatic, and no cases of hepatitis,
jaundice, or signs of liver dysfunction were reported.
Two patients had clinically important elevations in crea-
tine phosphokinase (CPK) activity. One patient in the
simvastatin 20 mg group had signs and symptoms consistent
with myopathy (defined as CPK 10 ULN with associ-
ated muscle symptoms). This patient reported mild myalgia
ending five days before the CPK elevation and discontinu-
ation of the study drug. A second patient, who was receiving
simvastatin monotherapy (40 mg), had a 10 ULN
increase in CPK activity (without associated muscle symp-
toms) that gradually declined while continuing the study
drug. For these two patients, the investigator considered
physical exercise a possible contributing factor to the in-
creased CPK, which returned to the normal range after
discontinuation of the study drug. Results of other labora-
tory tests, vital signs, electrocardiograms, and cardiopulmo-
nary examinations did not suggest any clinically important
differences between the coadministration and simvastatin
monotherapy groups.
DISCUSSION
Efficacy of coadministration of ezetimibe with simvastatin.
In this study, coadministration of ezetimibe plus simvastatin
was more effective in reducing plasma concentrations of
LDL-C than simvastatin or ezetimibe alone. Coadminis-
tration of ezetimibe with each dose of simvastatin resulted
in a significant LDL-C-lowering effect compared with each
corresponding dose of simvastatin alone (p  0.01). Fur-
thermore, the improvement was significantly greater than
that seen with a doubling of the simvastatin dose alone.
Coadministration of ezetimibe and simvastatin 10 mg
resulted in a similar mean percentage change in LDL-C as
simvastatin 80 mg alone. Thus, coadministration of
ezetimibe with the lowest dose of simvastatin reduced
LDL-C concentrations to a similar extent as increasing the
simvastatin dose eightfold. A further enhancement of the
LDL-C-lowering effect was obtained when ezetimibe was
coadministered with simvastatin 80 mg, resulting in a mean
percentage change from baseline of approximately 57%
versus 44% with simvastatin 80 mg alone. The percentage
reductions in plasma concentrations of LDL-C attained
with the four doses of simvastatin administered in this study
were consistent with those in the product labeling for
simvastatin (15).
Favorable effects of simvastatin on lowering TC, TG, and
apolipoprotein B concentrations and increasing HDL-C
concentrations were all significantly enhanced by coadmin-
istration with ezetimibe. Moreover, the coadministration of
ezetimibe and simvastatin significantly improved other risk
factors for coronary heart disease such as LDL-C:HDL-C
and TC:HDL-C ratios and non-HDL-C relative to sim-
vastatin alone.
Results of pilot clinical pharmacology studies (10,11)
suggesting that coadministration of ezetimibe and simva-
statin would have an enhanced effect on LDL-C reduction
have been confirmed in this larger Phase 3 study. In
addition, in a similarly designed factorial study (16), coad-
ministration of ezetimibe and atorvastatin provided signif-
icant incremental reductions in LDL-C (12.1%) and TG
(8.0%) concentrations, as well as increases in HDL-C
concentrations (3.0%) (p  0.01) compared with atorvasta-
tin alone. Therefore, the combination of the two different
mechanisms of action of these agents (inhibition of choles-
terol synthesis by simvastatin and inhibition of cholesterol
absorption in the intestine by ezetimibe) results in a sub-
stantial incremental benefit in LDL-C as well as providing
incremental beneficial effects on HDL-C and TG levels.
The incremental LDL-C reduction obtained with the
coadministration of a statin with ezetimibe provided signif-
icantly better LDL-C reductions compared with two dou-
blings of the statin dose and similar results to a third
doubling of the statin dose.
Safety of coadministration of ezetimibe with simvastatin.
The overall safety profile of the coadministration therapy
was generally similar to that of simvastatin alone and to
Table 4. Safety
Placebo
(n  70)
Ezetimibe 10 mg
(n  61)
All Simvastatin*
(n  263)
Ezetimibe 10 mg 
All Simvastatin*
(n  274)
All adverse events 49 (70%) 45 (74%) 190 (72%) 189 (69%)
Treatment-related adverse events 17 (24%) 11 (18%) 50 (19%) 54 (20%)
Gastrointestinal adverse events 7 (10%) 3 (5%) 16 (6%) 11 (4%)
Musculoskeletal system disorders 3 (4%) 1 (2%) 9 (3%) 6 (2%)
Discontinuations due to adverse events 3 (4%) 5 (8%) 14 (5%) 20 (7%)
Liver function tests
At least 3 ULN, 2 consecutive times
ALT† 0 0 2 (1%) 6 (2%)
AST 0 0 1 (1%) 2 (1%)
CPK
At least 10 ULN 0 0 2 (1%) 0
*All simvastatin  pool of all doses of simvastatin. †Ezetimibe plus simvastatin 20 mg (n  1), ezetimibe plus simvastatin 40 mg (n  4), and ezetimibe plus simvastatin 80
mg (n  1); alanine aminotransferase (ALT) elevations were asymptomatic and transient; 5 of the 6 patients had elevated ALT levels at baseline; 2 of the 6 patients continued
treatment while ALT returned to baseline level; 4 of the 6 patients discontinued study treatment (in accordance with the protocol safety rules).
AST  aspartate aminotransferase; CPK  creatine phosphokinase; ULN  upper limit of normal.
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placebo in this 12-week study. Generally, the adverse event
profiles were similar across treatment groups. There was no
evidence to suggest that the addition of ezetimibe to any
dose of simvastatin increased the risk of any nonlaboratory
adverse event. Furthermore, no pattern of a dose relation-
ship was evident with respect to simvastatin, administered
either alone or with ezetimibe.
Hepatobiliary function and CPK activity/myopathy were
carefully evaluated in view of the known effects of lipid-
lowering agents on these measures. Coadministration of
ezetimibe with low doses of simvastatin (10 and 20 mg)
produced similar or even greater LDL-C reductions com-
pared with the highest simvastatin dose (80 mg) without
altering the incidence of elevations in ALT/AST levels.
Although five of the six increases with ezetimibe and
simvastatin coadministration occurred in patients receiving
simvastatin doses of 40 mg or higher, only one was seen in
the ezetimibe plus simvastatin 80 mg group; the numbers
were insufficient to confirm a clear dose relationship across
the individual treatment groups. These asymptomatic in-
creases in transaminase activities may be the result of a
pharmacodynamic effect due to cholesterol reduction or
alterations in hepatic metabolism (17–20). Except for
sustained-release nicotinic acid, there is little evidence of
hepatotoxicity with any of the lipid-lowering drugs
(18,21,22).
The only CPK elevations 10 ULN occurred in the
simvastatin monotherapy group. The observed occurrences
of elevations in CPK activity and/or muscle-related adverse
events did not suggest any new or clinically meaningful
adverse effects of coadministration with ezetimibe beyond
that already documented for simvastatin or statins in gen-
eral. No cases of rhabdomyolysis were reported in this study.
Study limitations. Although the goal attainment analysis
was exploratory, the results indicated that more patients
were able to reach their LDL-C target with ezetimibe and
simvastatin coadministration than with simvastatin therapy
alone. This study was conducted while NCEP ATP II
guidelines were in effect. Before the database was locked,
new guidelines were established by ATP III; however, the
patient data had been collected to characterize the patients
according to the NCEP ATP II guidelines. Also, the trial
was of fairly short duration (12 weeks), so analysis of
long-term efficacy and safety is not possible.
Implications. The complementary mechanism of action of
ezetimibe and simvastatin may offer a new multitargeted
strategy for lipid management in patients with hypercho-
lesterolemia. Coadministration of ezetimibe with low-dose
simvastatin may be a well-tolerated treatment alternative to
high-dose simvastatin monotherapy. In addition, coadmin-
istration of ezetimibe and simvastatin has the potential to
increase the number of patients who can achieve the
recommended target lipid levels. In clinical practice,
ezetimibe may be coadministered with statins in patients
who have been unable to achieve LDL-C target concentra-
tions with statin monotherapy alone, as well as in patients at
risk for increased side effects at higher doses of statin
monotherapy. The need for less frequent statin dosage
adjustments may lead to improved patient compliance and
help more patients attain their LDL-C goals.
Conclusions. Coadministration of ezetimibe plus simva-
statin 10, 20, 40, or 80 mg was more effective in reducing
mean plasma concentrations of LDL-C than simvastatin or
ezetimibe alone. A similar reduction in plasma concentra-
tions of LDL-C was achieved with the coadministration of
ezetimibe 10 mg plus simvastatin 10 mg as with simvastatin
80 mg alone. Reductions in the plasma concentrations of
TC, TG, and apolipoprotein B and increases in the plasma
concentrations of HDL-C were all significantly enhanced
by the coadministration of ezetimibe plus simvastatin. The
coadministration of ezetimibe plus simvastatin was well
tolerated and had an overall safety profile similar to that of
simvastatin alone and to placebo. Coadministration of
ezetimibe and simvastatin offers a highly efficacious new
treatment strategy for lipid-regulating therapy in patients
with hypercholesterolemia.
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